Nirsevimab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), CIPM (Spain) and CONITEC (Brazil), among others, recommended or restricted nirsevimab, while PBAC (Australia) did not recommend it.
The record spans 3.3 years, opening at CIPM (Spain) on 11 May 2023 and running to 20 Sep 2026.
No assessment is on file from SMC (Scotland), AWMSG (Wales) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 19 of 19 records date from 2023 or later.
3 of these 19 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
CIPM (Spain) was first to assess nirsevimab, on 11 May 2023; NYE METODER (Norway) did not open a file until 20 Sep 2026 — a wide spread of 3.3 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 4 years in total.
6 of the 10 agencies here assessed nirsevimab more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for nirsevimab.
The full ledger for nirsevimab reads 11 recommended, 3 restricted, 2 no benefit and 1 advice, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 20 Sep 2026 | For forebygging av respiratorisk syncytialt virus (RSV) sykdom i nedre luftveier hos nyfødte og spedbarn med høy risiko … | introduced | source |
| AOTMIT (Poland) | 31 Jul 2026 | programu lekowego B.40 „Profilaktyka zakażeń wirusem RS | recommended conditionally | source |
| HAS (France) | 15 Jul 2026 | Re-assessment of SMR and ASMR | SMR substantial · ASMR IV | source |
| DMC (Denmark) | 27 May 2026 | Forebyggelse af RSV-sygdom i nedre luftveje hos nyfødte og spædbørn i løbet af deres første RSV-sæson | Delvist anbefalet | source |
| PHARMAC (New Zealand) | 28 Apr 2026 | Infant RSV protection | PTAC advice: High | source |
14 further decisions for nirsevimab, across 8 agencies, are not shown here. They include the most recent record on file, 20 Sep 2026 from NYE METODER (Norway); its outcome is in the subscriber dataset. They link to 10 further source documents.
Related molecules
- human normal immunoglobulin — same ATC class J06B — Immune sera and immunoglobulins
- bezlotoxumab — same ATC class J06B — Immune sera and immunoglobulins
- palivizumab — same ATC class J06B — Immune sera and immunoglobulins
- sotrovimab — same ATC class J06B — Immune sera and immunoglobulins
- guselkumab — also decided by NYE METODER in 2026Q3
- ponatinib — also decided by NYE METODER in 2026Q3
Coverage: 19 decisions for nirsevimab from 10 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class J06B — Immune sera and immunoglobulins. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.